此乃要件 請即處理 閣下如 對本通函任何方面或應採取之行動 有任何疑問，應 諮 詢 閣下之持牌證 券 交 易 商 或 註 冊 證 券 機 構、銀 行 經 理、律 師、專 業 會 計 師 或 其 他 專 業 顧 問。 閣下如已出售或轉讓 名 下 全 部 朝 聚 眼 科 醫 療 控 股 有 限 公 司 的 股 份，應 立 即 將 本 通函及隨附之代表委任表格送交買主或承讓人或經手買賣或轉讓之持牌證券 交 易 商 或 註 冊 證 券 機 構 或 其 他 代 理 商，以 便 轉 交 買 主 或 承 讓 人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 通 函 之 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 Chaoju Eye Care Holdings Limited 朝聚眼科醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2219） 建議授出發行新股及購回股份的一般授權 ...

Financial Performance - For the year ended December 31, 2024, the company reported revenue of RMB 1,405,454,000, representing an increase from RMB 1,369,505,000 in 2023, which is a growth of approximately 2.0%[5] - The gross profit for 2024 was RMB 611,302,000, with a gross margin of 43.5%, down from 45.4% in 2023[5] - The net profit for 2024 was RMB 186,210,000, resulting in a net profit margin of 13.2%, compared to 16.1% in the previous year[5] - The company reported a total equity of RMB 2,326,151,000 as of December 31, 2024, down from RMB 2,378,425,000 in 2023[5] - Total revenue reached RMB 1.405 billion, maintaining a healthy gross margin despite challenges from artificial lens procurement and DIP/DRG policies[15] - Net profit achieved RMB 186 million, with net cash flow from operating activities amounting to RMB 354 million, indicating strong financial health[15] - Total gross profit for the group was RMB 611.3 million for the year ended December 31, 2024, a decrease of 1.6% from RMB 621.1 million in 2023[37] - The company's adjusted net profit for the year ended December 31, 2024, is RMB 202.7 million, a decrease of 9.2% from RMB 223.1 million in 2023, with an adjusted net profit margin of 14.4% compared to 16.3% in the previous year[57] Operational Efficiency and Strategy - The company implemented a "Excellence Plan" to optimize management and resource allocation, enhancing operational efficiency across hospitals[12] - The company believes its cluster operation model enhances market penetration, operational efficiency, and profitability[9] - The company plans to enhance operational efficiency and service quality through systematic, standardized, professional, refined, and intelligent management strategies in 2025[16] - Marketing strategies were refined using data-driven approaches to improve marketing efficiency and ensure effective outreach to target patient groups[13] - Continuous investment in advanced medical equipment and precise pricing strategies for high-end ophthalmic services contributed to improved patient experiences[15] Market Expansion and Services - The company is focusing on expanding its consumer eye care services while maintaining its foundational eye care services, responding to the increasing consumer demand in China[7] - The group operates a network of 31 ophthalmology hospitals across 7 provinces, municipalities, and autonomous regions in China as of December 31, 2024[20] - The group aims to enhance market share in existing regions through strategic initiatives like the "Excellence Program" and "Wutong Program" while focusing on patient outcomes[19] - The group plans to continue investing in advanced medical equipment and treatment solutions to improve service quality and patient retention rates[25] - The consumption ophthalmology services accounted for 50.3% of total revenue in 2024, making it the primary revenue source for the group[24] - Basic ophthalmology services contributed approximately 49.6% to total revenue in 2024, marking it as another major revenue source[25] Human Resources and Talent Management - As of December 31, 2024, the group employed 1,464 full-time medical professionals, including 296 physicians, 625 nurses, and 543 other professionals[38] - The company has implemented systematic training and education programs for employees, ensuring a well-proportioned mix of medical professionals and enhancing clinical skills through both internal and external training[86] - The company is committed to maintaining gender diversity within its workforce and enhancing employee value as a key asset[124] Acquisitions and Investments - The group has made significant acquisitions in the healthcare sector, enhancing its service offerings and market presence[32] - The group has acquired multiple hospitals, including Bayannur Hospital and Beijing Clinic in September 2023, and Yinchuan Hospital in March 2023[32] - The group plans to continue expanding its network in the North China region and aims to acquire more hospitals in the near future[40] Financial Position and Cash Flow - The net cash inflow from operating activities for the year ended December 31, 2024, was RMB 354.4 million, down from RMB 372.6 million in 2023[61] - The company reported a net increase in cash and cash equivalents of RMB 317.3 million for the year ended December 31, 2024, compared to a decrease of RMB 481.3 million in 2023[61] - The total capital commitments as of December 31, 2024, amounted to approximately RMB 564 million, a decrease from RMB 715 million in 2023[66] Risk Management and Compliance - The company faces risks related to price controls and coverage limits under public health insurance plans, which may impact pricing of services and products[112] - The company has a credit risk management policy in place to monitor and manage potential losses from counterparties failing to meet obligations[77] - The company has maintained compliance with relevant laws and regulations, with no significant violations reported as of December 31, 2024[118] Shareholder and Governance - The company adopted a share incentive plan on May 10, 2022, granting a total of 16,330,994 shares to 311 employees and directors as of December 31, 2024, with a total allowable grant of 54,803,769 shares under the plan[85] - The company has established an audit committee consisting of three independent non-executive directors to oversee financial reporting and risk management[14] - All independent non-executive directors confirmed their independence for the period from January 1, 2024, to December 31, 2024[167] Environmental and Social Responsibility - The company has a commitment to environmental protection and has established policies for the proper handling and disposal of medical waste, ensuring compliance with applicable laws and regulations[115] - The company is committed to fulfilling social responsibilities and promoting employee welfare, aiming for sustainable growth[116]

朝聚眼科醫療控股有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號: 2219) Dear registered shareholder(s), 15 April 2025 Arrangement of Electronic Dissemination of Corporate Communications Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, ...

Chaoju Eye Care Holdings Limited 朝聚眼科醫療控股有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號: 2219) 15 April 2025 Dear non-registered shareholder(s), Arrangement of Electronic Dissemination of Corporate Communications Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that ...

Core Viewpoint - Chaoyue Eye Care (02219.HK) reported a revenue of 1.405 billion RMB for the fiscal year 2024, reflecting a year-on-year growth of 2.6%, while adjusted net profit reached 203 million RMB with a net profit margin of 14.4% [1] Financial Performance - The company achieved a net cash flow from operating activities of 354 million RMB, indicating strong cash management capabilities [1] - The gross profit margin was maintained at 43.5% despite industry policy adjustments, supported by cost control and process optimization [2] - A dividend of 0.25 HKD per share was declared, with a high payout ratio of 80%, showcasing stable cash flow management [3] Business Segments - Basic ophthalmology revenue increased by 6.7% to 698 million RMB, driven by optimized diagnostic services and personalized customer engagement [1] - Consumer ophthalmology revenue slightly decreased by 0.4% to 706 million RMB, influenced by overall economic downturn, with stable pricing adjustments [1] - The number of outpatient and inpatient visits grew by 2.9% and 71.2% respectively, due to the "regional center hospital + satellite clinic" management model [1] Strategic Initiatives - The company is advancing its "North China consolidation + Yangtze River Delta breakthrough" regional strategy, operating 31 eye hospitals and 29 optical centers across seven provinces and autonomous regions [1] - Chaoyue Eye Care is enhancing its application of artificial intelligence in diagnostic processes and service efficiency [1] - The company is focusing on expanding its network through new establishments and acquisitions while strengthening its smart healthcare system [1] Market Outlook - The high demand in the ophthalmology sector is supported by an aging population and increasing myopia prevention needs among youth, which drives the demand for basic eye care services [2] - The trend of consumption upgrades is gradually releasing the market potential for high-end services such as refractive surgery [2] - The company is adapting to the policy environment through its "Excellence Program," optimizing procurement processes and enhancing service efficiency [2] Social Responsibility - In 2024, the company will enhance its social value through public welfare projects, providing amblyopia screening and treatment for underprivileged children in Inner Mongolia [2] - Participation in the "Belt and Road Brightness Action" international medical assistance and conducting over a hundred eye health awareness activities, reaching thousands of families [2] Research and Development - The company led five research projects, published 18 papers, and obtained five patents during the year, laying the groundwork for technological upgrades [3] - The "Phoenix Plan" for human resources aims to attract high-end talent and promote integrated development of science, education, and research [3] Future Focus - Management plans to concentrate on three main areas by 2025: deepening the layout in North China and the Yangtze River Delta, expanding the scope of consumer eye care services, and advancing ESG (Environmental, Social, and Governance) system construction [3]

表格類別： 股票 狀態： 新提交 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02219 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 ...

發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 截至本公告日期，本公司董事會包括董事長兼執行董事張波洲先生；執行董事張小利女士、張俊峰先生及張光弟先生；非執行董事 Richard Chen MAO先生、李甄先生及張麗女士；以及獨立非執行董事何明光先生、郭紅岩女士、李建濱先生及寶山先生。 第 2 頁 共 2 頁 v 1.1.1 第 1 頁 共 2 頁 v 1.1.1 EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 朝聚眼科醫療控股有限公司 | | 股份代號 | 02219 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度之末期股息 | | 公告日期 | ...

Financial Performance - The group's revenue increased by 2.6% from RMB 1,369.5 million for the year ended December 31, 2023, to RMB 1,405.5 million for the year ended December 31, 2024[2]. - The group's profit before tax decreased by 12.2% from RMB 299.2 million to RMB 262.7 million, with a profit before tax margin dropping from 21.9% to 18.7%[2]. - The group's net profit fell by 15.6% from RMB 220.7 million to RMB 186.2 million, resulting in a net profit margin decline from 16.1% to 13.2%[3]. - The adjusted net profit under non-IFRS decreased by 9.1% from RMB 223.1 million to RMB 202.7 million, with the adjusted net profit margin dropping from 16.3% to 14.4%[3]. - The group's gross profit margin decreased from 45.4% to 43.5%[7]. - The group's EBITDA under non-IFRS was RMB 374.1 million, slightly down from RMB 377.3 million in the previous year[7]. - The total gross profit for the group was RMB 611.3 million, a decrease of 1.6% from RMB 621.1 million in the previous year[18]. - The company's net asset value was RMB 2,326,151 thousand, down from RMB 2,378,425 thousand in 2023, reflecting a decrease of 2.2%[96]. - The company reported a significant increase in cash and cash equivalents, reaching RMB 780,785 thousand, compared to RMB 463,437 thousand in 2023, an increase of 68.4%[95]. Revenue Sources - The consumption ophthalmology services accounted for 50.3% of total revenue in 2024, making it the primary revenue source for the group[14]. - Basic ophthalmology services contributed approximately 49.6% to total revenue in 2024, serving as another major revenue source[17]. - Revenue from consumer ophthalmology services decreased by 0.4% from RMB 709.2 million to RMB 706.4 million, indicating a slowdown in the Chinese consumer market[30]. - Revenue from basic ophthalmology services increased by 6.7% from RMB 654.0 million to RMB 697.8 million, driven by enhanced marketing activities and improved patient conversion rates[31]. Operational Metrics - Outpatient visits increased to 1,137,742 in 2024 from 1,128,719 in 2023, with an average spending per visit rising from RMB 698 to RMB 713[9]. - Inpatient visits rose to 72,120 in 2024 from 67,258 in 2023, while average spending per inpatient visit decreased from RMB 7,109 to RMB 6,914[9]. - The optical center recorded 105,354 customer visits in 2024, down from 120,184 in 2023, with average sales price increasing from RMB 806 to RMB 900[9]. Dividends and Shareholder Returns - The board proposed a final dividend of HKD 0.1193 per share for the year ended December 31, 2024, down from HKD 0.2208 per share in 2023[4]. - The total interim dividend declared and paid for the six months ended June 30, 2024, was approximately HKD 90.28 million (equivalent to RMB 82.5 million)[4]. - The company has declared a final dividend of HKD 0.2208 per share and a special dividend of HKD 0.0767 per share, totaling approximately HKD 205.5 million (approximately RMB 187.1 million) for the year ended December 31, 2023[88]. Employee and Operational Structure - As of December 31, 2024, the group employed a total of 1,464 full-time medical professionals, including 296 doctors, 625 nurses, and 543 other professionals[20]. - The company has 267 registered full-time ophthalmologists as of December 31, 2024, contributing to its medical expertise[79]. - The total employee benefit expenses increased to RMB 421,240 in 2024 from RMB 377,754 in 2023, reflecting a growth of 11.5%[115]. - Employee compensation includes basic salary, performance-related bonuses, and discretionary year-end bonuses, with regular performance evaluations for salary reviews[80]. Strategic Initiatives and Future Plans - The group plans to continue expanding its network in the North China region and aims to acquire more hospitals in the near future[26]. - The company plans to invest HKD 200 million in research and development for innovative eye care solutions over the next two years[132]. - The company aims to improve operational efficiency, targeting a 5% reduction in costs by optimizing supply chain management[132]. - Future guidance indicates a potential revenue growth of 10-15% annually over the next three years[132]. Financial Position and Liabilities - The total liabilities decreased to RMB 554,765 thousand from RMB 544,381 thousand in 2023, indicating a slight increase in financial obligations[96]. - The total interest-bearing borrowings as of December 31, 2024, amounted to RMB 40,629,000, compared to RMB 7,153,000 in 2023, showing a significant increase[126]. - Trade receivables increased by 33.6% from RMB 55.7 million for the year ended December 31, 2023, to RMB 74.4 million for the year ending December 31, 2024, due to growth in basic ophthalmic services[45]. Compliance and Governance - The company has confirmed compliance with corporate governance codes and standards since January 1, 2024[67]. - The audit committee and independent auditors confirmed that the annual performance for the year ending December 31, 2024, complies with applicable accounting standards and regulations[84]. - The company has established an audit committee consisting of three independent non-executive directors to oversee financial reporting and risk management[70].

（於開曼群島註冊成立的有限公司） （股份代號：2219） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Chaoju Eye Care Holdings Limited 朝聚眼科醫療控股有限公司 (1) 聯席公司秘書辭任； (2) 委任聯席公司秘書；及 (3) 豁免嚴格遵守上市規則第3.28及8.17條 I. 聯席公司秘書辭任 朝聚眼科醫療控股有限公司（「本公司」，連同其附屬公司統稱為「本集團」）董事（「董 事」）會（「董事會」）謹 此 宣 佈，解 淳 女 士（「解女士」）已 辭 任 本 公 司 聯 席 公 司 秘 書（「聯席公司秘書」），自 二 零 二 五 年 三 月 十 七 日 起 生 效，以 投 放 更 多 時 間 處 理 其 他 事 務。 解 女 士 確 認，其 與 董 事 會 概 無 任 何 意 見 分 歧，亦 無 其 他 ...

朝 聚 眼 科 醫 療 控 股 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱 為「本集團」）董 事（「董 事」）會（「董事會」）謹 此 公 佈，董 事 會 會 議 將 於 二 零 二 五 年 三 月 二 十 六 日（星 期 三） 舉 行，藉 以（其 中 包 括）考 慮 及 批 准 本 集 團 截 至 二 零 二 四 年 十 二 月 三 十 一 日 止 年 度 之 全 年 業 績 及 其 發 佈，並 考 慮 建 議 派 發 末 期 股 息（如 有）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Chaoju Eye Care Holdings Limited 朝聚眼科醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2219） 董事會會議日期 承董事會命 朝聚眼科醫療控股有限公司 主 席 張波洲 香 ...